Prothena Corporation plc
NASDAQ:PRTABiotechnology
+$0.33 today
- Market cap
- $428.77M
- Beta
- -0.32
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$2.81
Volume 0.76M
Average 0.51M
PRTA EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Prothena Corporation plcNASDAQ: PRTA
EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026
EPS (Diluted) turns positive
Q1 FY2026 EPS (Diluted) was $0.6, compared with -$1.12 a year earlier. Trailing-twelve-month EPS (Diluted) was -$2.82.
Context
- EPS (Diluted) grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 4 analysts of -$0.02 (+99.5%) for the fiscal year ending Dec 2026, a step up from the -99.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $0.6+250.0% QoQ
- Last fiscal yearDec 2025
- -$4.53-99.6% YoY
- LTMMar 2026
- -$2.82-35.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +153.6% | +83.3% | -70.2 pp |
| 1 year | -99.6% | +99.5% | +199.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (4.53) USD
- Year-over-year change
- -99.6%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (4.53) | -99.6% |
| FY2024 | 2024-12-31 | (2.27) | +17.8% |
| FY2023 | 2023-12-31 | (2.76) | -11.7% |
| FY2022 | 2022-12-31 | (2.47) | -279.0% |
| FY2021 | 2021-12-31 | 1.38 | — |
EPS (Diluted) vs competitors
How PRTA compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
- Its year-over-year change of -35.6% is the 8th highest of 10, against a peer median of -1.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $5.65 USD | -46.1% | -24.9% | |
| LTM Mar 2026 | -$0.26 USD | +64.6% | — | |
| LTM Dec 2025 | -$0.46 USD | +15.7% | — | |
| LTM Mar 2026 | -CHF 0.66 CHF | -26.9% | — | |
| LTM Mar 2026 | -$1.22 USD | -3.4% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$1.33 USD | +17.4% | — |
| LTM Mar 2026 | -$1.87 USD | +3.6% | — | |
| LTM Mar 2026 | -$2.82 USD | -35.6% | — | |
| LTM Jun 2026 | -$2.84 USD | -1.4% | — | |
| LTM Jun 2026 | -$16.89 USD | -243.3% | — | |
| Peer median (excluding PRTA) | — | -1.4% | -24.9% | |
Competitors are the stored peer set for PRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 200.58M | 53.91M | 91.37M | 135.16M | 9.68M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 3.7M |
| Gross Profit | 200.58M | 53.91M | 91.37M | 135.16M | 5.98M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 61.8% |
| Research & Development | 82.28M | 135.56M | 220.57M | 222.52M | 134.85M |
| Selling, General & Admin | 46.32M | 49.9M | 61.84M | 67.2M | 59.39M |
| Operating Expenses | 128.6M | 185.46M | 282.41M | 289.72M | 190.54M |
| Depreciation & Amortization | 1.12M | 744K | 928K | 893K | 3.7M |
| EBITDA | 73.04M | (124.86M) | (159.55M) | (128.04M) | (197.13M) |
| EBITDA Margin | 36.4% | -231.6% | -174.6% | -94.7% | -2035.6% |
| Operating Income | 71.98M | (131.56M) | (191.04M) | (154.56M) | (184.56M) |
| Operating Margin | 35.9% | -244.1% | -209.1% | -114.4% | -1905.8% |
| Interest Income | 42K | 6.35M | 31.01M | 25.82M | 14.14M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (54K) | 5.95M | 30.56M | 25.63M | (16.27M) |
| Income Before Tax | 71.92M | (125.61M) | (160.48M) | (128.93M) | (200.83M) |
| Pre-Tax Margin | 35.9% | -233.0% | -175.6% | -95.4% | -2073.8% |
| Income Tax Expense | 4.95M | (8.66M) | (13.45M) | (6.62M) | 43.26M |
| Net Income | 66.98M | (116.95M) | (147.03M) | (122.31M) | (244.09M) |
| Net Margin | 33.4% | -217.0% | -160.9% | -90.5% | -2520.6% |
| EPS (Basic) | 1.51 | (2.47) | (2.76) | (2.27) | (4.53) |
| EPS (Diluted) | 1.38 | (2.47) | (2.76) | (2.27) | (4.53) |
| Weighted Avg Shares | 44.23M | 47.37M | 53.22M | 53.77M | 53.83M |
| Weighted Avg Shares (Diluted) | 48.46M | 47.37M | 53.22M | 53.77M | 53.83M |
Prothena Corporation plc
NASDAQ:PRTA
Intrinsic Alpha fair value
Locked
Current Price
$8.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.